The ruling is ablow to the Trump administration and its plan to bring down drugprices. (Photo: Shutterstock)
More than a year after the Department of Health and HumanServices finalized a rule that would require drugmakers to includepricing information in TV ads, the rulecontinues to be mired down in court challenges.
In the latest blow, a three-judge federal appealscourt has ruled that the HHS does not have the authority to compelthe price disclosures. The decision affirms a previous ruling by afederal judge last summer in response to a lawsuit filed by Merck& Co., Eli Lilly & Co. and Amgen Inc..
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Emily Payne
Emily Payne is director, content analytics for ALM's Business & Finance Markets and former managing editor for BenefitsPRO. A Wisconsin native, she has spent the past decade writing and editing for various athletic and fitness publications. She holds an English degree and Business certificate from the University of Wisconsin.
